ÈËÆÞÖгöÊÓƵ

Kathleen C. Kerrigan
( out of 54 reviews )

Kathleen C. Kerrigan, DO

Languages spoken: English

Clinical Locations

Sugar House ÈËÆÞÖгöÊÓƵ Center

Salt Lake City
801-581-2000

  • Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Osteopathic Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 54 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 16, 2024
    HUNTSMAN CANCER CENTER

    I have had care from 4 different oncologists over my 2 experiences with serious cancer. I would rate Dr Kerrigan as number one in her level of care and concern for my well being.

    October 14, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Kerrigan has been my doctor now for four years. I trust her and I know she is taking good care of me. She is always caring and supportive toward me, and available if I need anything. Thank you......... Gracias!!!

    October 06, 2024
    HUNTSMAN CANCER CENTER

    She's very professional and cute

    September 27, 2024
    SUGAR HOUSE HEALTH CENTER

    easy to work with. professional

    September 26, 2024
    SUGAR HOUSE HEALTH CENTER

    She is all business with a pleasant smile! She has great doctor to patient rapport.

    September 23, 2024
    SUGAR HOUSE HEALTH CENTER

    Professional and easy to talk to.

    September 21, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Kerrigan has been my doctor now for four years and I can say I wouldn't trade her for anyone else. She is patient, supportive and caring of me. Thank you....... Gracias!!! Her nurse Melissa is always available if I need anything or have any questions and I get a quick response. Thank you again to both of you for your continued professional care for me. I always feel better when I leave my visit that day. Gracias!!!!

    September 21, 2024
    SUGAR HOUSE HEALTH CENTER

    If your looking for true support, experience and understanding of what your treatment needs are, Kathleen Kerrigan is an excellent doctor.

    September 12, 2024
    SUGAR HOUSE HEALTH CENTER

    She's an excellent physician. And attentive to my concerns. I have reached out to her on three occasions via email, and she has responded promptly each time.

    See More Patient Comments

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Osteopathic Medical Examiners

    Education history

    Fellowship Hematology & Oncology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Fellow
    Hematology & Oncology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Fellow
    Research Fellow Internal Medicine - Ohio State ÈËÆÞÖгöÊÓƵ Resident
    Research and Scholarly Advancement Fellowship (RSAF) program - Ohio ÈËÆÞÖгöÊÓƵ Heritage College of Osteopathic Medicine Research Fellow
    Doctoral Training Osteopathic Medicine - Ohio ÈËÆÞÖгöÊÓƵ Heritage College of Osteopathic Medicine D.O.
    Ohio State ÈËÆÞÖгöÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D (2022). Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf), 96(5), 734-742. ()
    2. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. ()
    3. Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3). ()
    4. Stetson PD, McCleary NJ, Osterman T, Ramchandran K, Tevaarwerk A, Wong T, Sugalski JM, Akerley W, Mercurio A, Zachariah FJ, Yamzon J, Stillman RC, Gabriel PE, Heinrichs T, Kerrigan K, Patel SB, Gilbert SM, Weiss E (2022). Adoption of Patient-Generated ÈËÆÞÖгöÊÓƵ Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. J Natl Compr Canc Netw, 1-6. ()
    5. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. ()
    6. Kerrigan K, Chan J, Vagher J, Kohlmann W, Naumer A, Anson J, Low S, Schiffman J, Maese L (2021). Lung Cancer in Li Fraumeni Syndrome. . JCO Precis Oncol, 23(5).
    7. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer.
    8. Kerrigan K, Patel SB, Haaland B, Ose D, Chalmers AW, Haydell T, Meropol NJ, Akerley WL (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. 16(4), 313-323.
    9. Kerrigan K, Shoben A, Otterson G (2016). Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer, 17(6), 523-527. ()
    10. Kerrigan KOtterson G (2016). Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit Setting. Am J Respir Crit Care Med.

    Review

    1. Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123. ()
    2. Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki M, Pinato DJ, Puri S (2021). The Role of Gut Microbiome in Modulating Response to Immune Checkpoint Inhibitor Therapy in Cancer. [Review]. Ann Transl Med.

    Case Report

    1. Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 26(1), 224-227. ()
    2. Griswold CR, Kerrigan K, Patel SB (2019). Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol, 12(3), 866-871. ()

    Abstract

    1. Owonikok TK, Elliot A, Dwivedi B, Ivanov A, Sica G, Kerrigan K, et al (2022). Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC) [Abstract].
    2. Russell J, Kerrigan K, Yang D (2022). Circulating tumor DNA profiling and serial analysis in salivary gland carcinomas reveal unique mutational subsets and actionable alterations [Abstract].
    3. Kerrigan K, Puri S, Sinnott JHaaland B, Akerley W, Patel SB (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis. [Abstract]. 16(3), 89.05.
    4. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. [Abstract]. 16(3 S122-123), OA09.05.
    5. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy. [Abstract]. 16(3, S199), FP05.01.
    6. Puri S, Patel S, Chalmers A, Kerrigan K, Cannon L, George S, Boucher K, Akerley W (2021). Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC [Abstract]. 16(3, S344), P15.02.
    7. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer   [Abstract]. 14(10), S307-308.
    8. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers   [Abstract]. 14(10), P1.01-35.

    Video/Film/CD/Web/Podcast

    1. Kerrigan K (2019). Incorporation PROs Can Improve Patient Care and Outcomes [Web]. OncLive Oncology Fellows Magazine.